Literature DB >> 30310231

Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs.

Delphine Charvin, Rossella Medori, Robert A Hauser, Olivier Rascol.   

Abstract

This corrects the article DOI: 10.1038/nrd.2018.136.

Entities:  

Year:  2018        PMID： 30310231     DOI： 10.1038/nrd.2018.184

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


  9 in total

1.  Brain Hepcidin Suppresses Major Pathologies in Experimental Parkinsonism.

Authors:  Tuo Liang; Zhong-Ming Qian; Ming-Dao Mu; Wing-Ho Yung; Ya Ke
Journal:  iScience       Date:  2020-06-19

Review 2.  In vitro Models of Neurodegenerative Diseases.

Authors:  Anna Slanzi; Giulia Iannoto; Barbara Rossi; Elena Zenaro; Gabriela Constantin
Journal:  Front Cell Dev Biol       Date:  2020-05-13

3.  Sphingolipids in neuroinflammation: a potential target for diagnosis and therapy.

Authors:  Ju Youn Lee; Hee Kyung Jin; Jae-Sung Bae
Journal:  BMB Rep       Date:  2020-01       Impact factor: 4.778

Review 4.  Targeting the cholinergic system in Parkinson's disease.

Authors:  Changliang Liu
Journal:  Acta Pharmacol Sin       Date:  2020-03-04       Impact factor: 6.150

Review 5.  Venoms as an adjunctive therapy for Parkinson's disease: where are we now and where are we going?

Authors:  Parisa Gazerani
Journal:  Future Sci OA       Date:  2020-11-30

6.  C-Phycocyanin-derived Phycocyanobilin as a Potential Nutraceutical Approach for Major Neurodegenerative Disorders and COVID-19- induced Damage to the Nervous System.

Authors:  Giselle Pentón-Rol; Javier Marín-Prida; Mark F McCarty
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.708

Review 7.  Innovative treatment targeting gangliosides aimed at blocking the formation of neurotoxic α-synuclein oligomers in Parkinson's disease.

Authors:  Nouara Yahi; Coralie Di Scala; Henri Chahinian; Jacques Fantini
Journal:  Glycoconj J       Date:  2021-07-30       Impact factor: 2.916

8.  Microglia-targeting nanotherapeutics for neurodegenerative diseases.

Authors:  Nanxia Zhao; Nicola L Francis; Hannah R Calvelli; Prabhas V Moghe
Journal:  APL Bioeng       Date:  2020-09-08

9.  The DJ1-Nrf2-STING axis mediates the neuroprotective effects of Withaferin A in Parkinson's disease.

Authors:  Miao Zhao; Bingwei Wang; Chenyu Zhang; Zhijie Su; Bingbing Guo; Yun Zhao; Ruimao Zheng
Journal:  Cell Death Differ       Date:  2021-03-24       Impact factor: 15.828
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.